Medtronic MICSIMPLANT3 Users Manual

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

The following are trademarks of Medtronic.
Active Can, CapSure, Cardiac Compass, Flashback, GEM, GEM DR, Marker Channel,

Marquis II, Medtronic, PR Logic, Patient Alert, Quick Look, Sigma

198483001 C Medtronic Confidential Composed:

MedtronCRM B

xxxx-xx-xx 11:48

,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxx
Printing instructions: doc#xxxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table of Contents

1 Description 3
2 Indications and usage 3
3 Contraindications 3
4 Warnings and precautions 3

4.1 Storage and handling 4

4.2 Resterilization 4

4.3 Device operation 4

4.4 Lead evaluation and lead connection 5

4.5 Follow-up testing 5

4.6 Explant and disposal 6

4.7 Medical therapy hazards 6

4.8 Home and occupational environments 7

5 Adverse events 8

5.1 Observed adverse events 8

5.2 Potential adverse events 10

6 Clinical studies 11

6.1 Acute study 11

6.2 Implant study 11

7 Patient selection and treatment 15

7.1 Individualization of treatment 15

7.2 Specific patient populations 15

8 Patient counseling information 16

9 Conformance to standards 16
10 How supplied 16
11 Clinician use information 16

11.1 Physician training 16

11.2 Directions for use 16

11.3 Maintaining device effectiveness 17

12 Patient information 17
13 Implant procedure 17

13.1 Pre-operative programming 18

13.2 Testing lead operation 18

13.3 Connecting leads to the implanted device 19

13.4 Defibrillation threshold testing 20

13.5 Placing the device 21

13.6 Programming 21

13.7 Replacing an old ICD 21

14 Feature summary 22

14.1 Tachyarrhythmia operations 22

14.2 Pacing operations 22

1

198483001 C Medtronic Confidential Composed: 2xxxx-xx-xx 11:48

MedtronCRM B,Cxxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

14.3 Monitoring operations 23

15 Product specifications 23

15.1 Physical specifications (nominal) 23

15.2 Replacement indicators 23

15.3 Projected longevity 24

15.4 Magnet behavior 26

15.5 Functional parameters 26

2

198483001 C Medtronic Confidential Composed:

MedtronCRM B

xxxx-xx-xx 11:48

,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

1 Description

The Mode lXXXX Marquis II DR Implantable Cardioverter Defibrillator (ICD) System is a multiprogrammable,
implantable cardioverter defibrillator that monitors and regulates a patient’s heart rate byproviding ventricular
arrhythmia therapy, and single or dual chamber rate responsive bradycardia pacing.

The Model XXXX Marquis II DR ICD, along with commercially available pace/sense leads and cardioversion/
defibrillation leads, constitutes the implantable portion of the ICD system. The lead systems for the
Marquis II DR system are implanted using standard transvenous placement techniques.

The Model 9790C programmer, Model 9966 software,Model 9466 patient magnet, Model 9322 SmartMagnet
and Model 9767 (or Model 9767L) programming head constitute one external portion of the ICD system.
The Model 2090 programmer is compatible. Programmers from other manufacturers are not compatible.

Contents of sterile package – The sterile package contains one implantable cardioverter defibrillator, one
torque wrench, and one DF–1 pin plug.

About this manual – This document is intended primarily as an implant manual. Regular patient
follow-up sessions should be scheduled after implant. Follow-up procedures such as monitoring battery
measurements and confirming therapy parameters are described in the manual included with the software
supporting the Model XXXX Marquis II DR ICD. (To obtain additional copies of this manual, contact your
Medtronic representative.)

2 Indications and usage

The implantable cardioverter defibrillator is intended to provide ventricular antitachycardia pacing and
ventricular defibrillation for automated treatment of life threatening ventricular arrhythmias.

3 Contraindications

The Marquis II DR system is contraindicated for

patients whose tachyarrhythmias may have transient or reversible causes, such as: acute myocardial

•

infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia, or sepsis.
patients with incessant VT or VF

•

patients who have a unipolar pacemaker

•

patients whose primary disorder is bradyarrhythmiasor atrial arrhythmias

•

4 Warnings and precautions

Avoiding shock during handling – Program tachyarrhythmia detection Off during surgical implant and

explant orpost-mortem procedures becausethe ICD can deliver a serious shock if you touch the defibrillation
terminals while the ICD is charged.

Electrical isolation during implantation – Do not permit the patient to contact grounded equipment,
which could produce hazardous leakage current during implantation. Resulting arrhythmia induction could
result in the patient’s death.

Lead system – Do not use another manufacturer’s lead system without demonstrated compatibility, as
undersensing of cardiac activity and failure to deliver necessary therapy could result.

Resuscitation availability – Do not perform ICD testing unless an external defibrillator and medical
personnel skilled in cardiopulmonary resuscitation (CPR) are readily available.

3

198483001 C Medtronic Confidential Composed: 2xxxx-xx-xx 11:48

MedtronCRM B,C xxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#xxxx refer to ’Implant manuals’ row in the applicable table.

4.1 Storage and handling

Checking and opening the package – Beforeopening the sterile package tray,visually check for any signs

of damage that might invalidate the sterility of its contents. Return damaged packages to the manufacturer.
For instructions on opening the sterile package, see the diagram inside the lid of the shelf box.

Device storage – Store the device in a clean area, away from magnets, kits containing magnets, and
sources of electromagnetic interference to avoid device damage.

Dropped device – Do not implant the device if it has been dropped on a hard surface from a height of 30 cm
(12 in) or more after removal from its packaging.

Equilibration – Allow the device to reach room temperature before programming or implanting, because
rapid temperature changes could affect initial device function.

Temperature limits – Store and transport the package between -18
“Use By” Date – Do not implant the device after the “Use By” date because the battery longevity could

be reduced.



C (0F) and +55C (+131F).

4.2 Resterilization

Medtronic has sterilized the device package contents with ethylene oxide prior to shipment. Resterilization is
necessary only if the seal on the sterile package is broken. (Resterilization does not affect the "Use By"
date.) If necessary, resterilize with ethylene oxide using a validated sterilization process, observing the
following precautions:

Do not resterilize the device using an autoclave, gamma radiation, organic cleaning agents (such as

•

alcohol, acetone, etc.), or ultrasonic cleaners.
Do not resterilize the device more than twice.

•

Do not exceed 55

•



C (131F) or 103 kPa (15 psi) when sterilizing.

4.3 Device operation

Accessories – The device may be used only with accessories, parts subject to wear and disposable items,

of which the completely safe use on safety and technical grounds has been demonstrated by a testing
agency approved for the testing of the device.

Battery depletion – Battery depletion will eventually cause the device to cease functioning and should be
carefully monitored. Cardioversion and defibrillation are high energy therapies and may quickly deplete
the battery and shorten the device longevity. An excessive number of charging cycles will also shorten
the longevity.

Charge Circuit Timeout or Charge Circuit Inactive – Replace the device immediately if the programmer
displays a Charge Circuit Timeout or Charge Circuit Inactive message.

Concurrent pacemaker use – If a pacemaker is used concurrently with the ICD, verify that the ICD will not
sense the pacemaker output pulses. Program the pacemaker so that pacing pulses are delivered at intervals
longer than the ICD tachyarrhythmia detection intervals.

End of Life (EOL) indicator – Replace the device immediately if the programmer displays an End of
Life (EOL) symbol.

Higher energy on the output capacitor – A higher than programmed energy can be delivered to the
patient when the device has been previously charged to a higher energy and the energy is still present on
the output capacitors.

Lead compatibility – Do not use another manufacturer’s lead system without demonstrated compatibility as
undersensing of cardiac activity and failure to deliver necessary therapy could result.

Medical treatment influencing device operation – The electrophysiological characteristics of a patient’s
heart can alter over time and the programmed therapies may become ineffective and even dangerous to the
patient. This is especially to be considered when the patient’s drug treatment has changed.

4

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Pacemaker dependent patients – Always program Ventricular Safety Pacing (VSP) On for pacemaker
dependent patients.

Programmers – Use only Medtronic programmers, application software, and accessories to communicate
with the device.

Use of a magnet – Positioning a magnet over the device suspends detection and treatment but does not
alter bradycardia therapy. The programming head contains a magnet that can suspend detection, but if
telemetry between the device and programmer is established, detection is not suspended.

4.4 Lead evaluation and lead connection

Use only ethylene oxide for lead resterilization. Do not resterilize more than one time.

•

Do not tie a ligature directly to the lead body,tie it too tightly, or otherwise create excessive strain at

•

the insertion site as this can damage the lead.
Do not immerse leads in mineral oil, silicone oil, or any other liquid.

•

Do not grip the lead with surgical instruments.

•

Do not use excessive force or surgical instruments to insert a stylet into a lead.

•

Use the same polarity evaluated during testing when connecting the leads to the ICD to ensure

•

defibrillation effectiveness.
Do not fold, alter, or remove any portion of the patch because doing so could compromise electrode

•

function or longevity.
Do not use ventricular transvenous leads in patients with tricuspid valvedisease or a mechanical

•

prosthetic tricuspid valve. Use with caution in patients with a bioprosthetic valve.
Use the correct suture sleeve (when needed) for each lead to immobilize the lead and protect it against

•

damage from ligatures.
Ensure that the defibrillation lead impedance is greater than 20

•

damage the ICD.
Do not kink the leads. Kinking leads can cause additional stress on the leads, possibly resulting

•

in lead fracture.
Do not suture directly over the lead body as this may cause structural damage. Use the lead anchoring

•

sleeve to secure the lead lateral to the venous entry site.
Lead or Active Can electrodes in electrical contact during a high voltage therapy could cause current to

•

bypass the heart, possibly damaging the ICD and leads. While the ICD is connected to the leads, make
sure that no therapeutic electrodes, stylets, or guidewires are touching or connected by an accessory
low impedance conductive pathway. Move objects made from conductive materials (e.g., an implanted
guidewire) well away from all electrodes before a high voltage shock is delivered.

Make sure to cap any pacing lead that is abandoned rather than removed to ensure that the lead does

•

not become a pathway for currents to or from the heart.
Make sure to plug any unused lead port in the device to protect the ICD.

•

Refer to the lead technical manuals for specific instructions and precautions about lead handling.

•



. An impedance below 20could

4.5 Follow-up testing

Ensure that an external defibrillator and medical personnel skilled in cardiopulmonary resuscitation

•

(CPR) are present during post-implant ICD testing should the patient require external rescue.
Be aware that changes in the patient’s condition, drug regimen, and other factors may change the

•

defibrillation threshold (DFT), which may result in nonconversion of the arrhythmia post-operatively.
Successful conversion of ventricular fibrillation or ventricular tachycardia during testing is no assurance
that conversion will occur post-operatively.

5

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

4.6 Explant and disposal

Interrogate the ICD, program VF and VT Detection Off, and disable ICD functions prior to explanting,

•

cleaning, or shipping the ICD to prevent unwanted shocks.
Explant the ICD postmortem. In some countries, explanting battery-operated implantable devices is

•

mandatory because of environmental concerns; please check your local regulations. In addition, if
subjected to incineration or cremation temperatures, the device could explode.

Medtronic implantable devices are intended for single use only. Do not resterilize and re-implant

•

explanted devices.
Please return explanted devices to Medtronic for analysis and disposal. See the back cover for mailing

•

addresses.

4.7 Medical therapy hazards

Diathermy – Peoplewith metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs),

and accompanying leads should not receive diathermy treatment. The interaction between the implant and
diathermy can cause tissue damage, fibrillation, or damage to the device components, which could result in
serious injury, loss of therapy, and/or the need to reprogram or replace the device.

Electrosurgical cautery – Electrosurgical cautery could induce ventricular arrhythmias and/or fibrillation,
or may cause implanted device malfunction or damage. If electrocautery cannot be avoided, observe the
following precautions to minimize complications:

Have temporary pacing and defibrillation equipment available.

•

Program the implanted device to the DOO mode.

•

Suspend tachyarrhythmiadetection using a magnet, or turn detection Off using the programmer.

•

Avoid direct contact with the implanted device or leads. If unipolar cautery is used, position the ground

•

plate so that the current pathway does not pass through or near the implanted device system (minimum
of 15 cm [6 in]).

Use short, intermittent, and irregular bursts at the lowest feasibleenergy levels.

•

Use a bipolar electrocautery system, where possible.

•

External defibrillation – External defibrillation may damage the implanted deviceor may result in temporary
and/or permanent myocardial damage at the electrode tissue interface as well as temporary or permanent
elevated pacing thresholds. Attempt to minimize the voltage potential across the device and leads by
following these precautions:

Use the lowest clinically appropriate energy output.

•

Position defibrillation patches or paddles as far from the device as possible (minimum of 15 cm [6 in]),

•

and perpendicular to the implanted device-lead system.
If an external defibrillation was delivered within 15 cm (6 in) of the device, contact your Medtronic

representative.

High-energy radiation – Diagnostic X-ray and fluoroscopic radiation should not affectthe device; however,
high-energy radiation sources suchas cobalt 60 or gamma radiation should not bedirected at the device. If a
patient requires radiation therapy in the vicinity of the device, place lead shielding over the implant site as a
precaution against radiation damage.

Lithotripsy – Lithotripsy may permanently damage the implanted device if it is at the focal point of the
lithotripsy beam. If lithotripsy must beused, temporarily turn off ICD therapiesduring the lithotripsy procedure
and keep the focal point of the lithotripsy beam at least 2.5 to 5 cm (1 to 2 in) from the implanted device.

Magnetic resonance imaging (MRI) – Magnetic resonance imaging (MRI) should not be used on patients
who have an implanted cardiac devicebecause of the potential damage to the implanted device.

6

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxx
Printing instructions: doc#xxxxxxx refer to ’Implant manuals’ row in the applicable table.

Radio frequency (RF) ablation – Radio frequency ablation procedure in a patient with an implanted cardiac
device could cause implanted device malfunction or damage. To minimize the risks from radio frequency
ablation,

Have temporary pacing and defibrillation equipment available.

•

Program the implanted device to the DOO mode.

•

Suspend tachyarrhythmiadetection using a magnet, or turn detection Off using the programmer.

•

Avoid direct contact between the ablation catheter and the implanted lead or device.

•

Position the ground plate so that the current pathway does not pass through or near the implanted

•

device system (minimum of 15 cm [6 in]).

Therapeutic ultrasound – Exposure of the device to therapeutic ultrasound is not recommended as it may
permanently damage the device. Damage to the device may affect therapy.

4.8 Home and occupational environments

Cellular phones – Marquis

interacting with device operation. To further minimize the possibility of interaction, observe the following
cautions:

Maintain a minimum separation of 15 cm(6 in) between the device and the hand-held telephone handset.

•

Maintain a minimum separation of 30 cm (12 in) between the device and any antenna transmitting

•

above 3 watts.
Hold the handset to the ear furthest from the implanted device.

•

Do not carry the handset within 15 cm (6 in) of the implanted device (even if the handset is not on).

•

The ICD has been tested using the ANSI/AAMI PC-69 standard to ensure compatibility with hand-held
wireless and PCS phones and other similar power hand-held transmitters. These transmission technologies
represent the majority of thecellular telephones in use worldwide. The circuitry of this device,when operating
under nominal conditions, has been designed to eliminate any significant effectsfrom the cellular telephones.

Commercial electrical equipment – Commercial electrical equipment such as arc welders, induction
furnaces, or resistance welders could generate enough EMI to interfere with device operation if approached
too closely.

Communication equipment – Communication equipment such as microwavetransmitters, line power
amplifiers, or high-power amateur transmitters could generate enough EMI to interfere with device operation
if approached too closely.

Electric or magnetic interference (EMI) – Patients should be directed to avoid devices that generate strong
electric or magnetic interference (EMI). EMI could cause malfunction or damage resulting in preventionof
proper programming, or confirmation, non-detection or delivery of unneeded therapy. Moving awayfrom the
interference source, or turning it off, usually allows the device to return to its normal mode of operation.

Electronic article surveillance (EAS) – EAS equipment such as retail theft prevention systems may interact
with the implanted device. Patients should be advised to walk directly through, and not to remain near an
EAS system longer than is necessary.

High voltage lines – High voltage power transmission lines could generate enough EMI to interfere with
device operation if approached too closely.

Home appliances – Home appliances which are in good working orderand properly grounded do not usually
produce enough EMI to interfere with deviceoperation. There are reports of temporary disturbances caused
by electric hand tools or electric razors used directly over the implant site.

Static magnetic fields – Patients should avoid equipment or situations where they would be exposed to
static magnetic fields (greater than 10 gauss or 1 millitesla) since it could suspend detection. Examples of
magnetic sources that could interfere with normal device operation include: stereo speakers, bingo wand,
extractor wand, magnetic badges, or magnetic therapy products.

II DR ICDs contain a filter that prevents most cellular phone transmissions from

7

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxx
Printing instructions: doc#xxxx; refer to ’Implant manuals’ row in the applicable table.

5 Adverse events

5.1 Observed adverse events

Clinical studies were not performed on the Marquis
and the GEMDR, clinical data generated by the GEM DR implant study was used to support the Marquis II DR.

The Clinical study of the GEM DR system (approved October 1998) included 300 ICDs implanted in 300
patients worldwide, and 297 Model 6940 CapSure Fix leads implanted in 295 patients worldwide. Total
ICD exposure was 828 device months. Individual patient exposure averaged 2.8 months (ranging from
0 to 5.3 months).

Each adverse event was reviewed by an independent clinical events committee to determine whether it
was related to the ICD system and/or the implantation procedure. There were a total of 15 deaths in the
300 patient clinical study; all were judged to be non-ICD related by the clinical events committee. Table 1
reports the causes of patient death during the clinical study in descending order of frequency. Except where
noted, all deaths were non-sudden cardiac deaths.

Table1. Patient deaths during the clinical study performed on GEM DR (approved Oct. 1998) (N=300)

Cause of Deaths (15 deaths total) # of Patients

Congestive heart failure

Cardiac and/or respiratory arrest or failure

Cardiogenic shock

Electromechanical dissociation

Ischemic cardiomyopathy

Pneumonia

a

One sudden cardiac death.

In the 300 patient clinical study one (1) device was explanted due to inappropriate VT detections.
The following adverse events were observed during the implant procedure (prior to skin closure): helix

extension failure (4 patients); cut in ventricular lead (1 patient); ST elevation (1 patient); electromechanical
dissociation (1 patient).

Table 2 and Table 3 report the adverse events attributed to the ICD system and/or implant procedure, on a
per patient and per patient-year basis in descending order of frequency. The tables list complications and
observations that occurred more than once. Complications and observations that occurred only once
are listed following Table2 and following Table 3.

II DR. Because of the similarity between the Marquis II DR

When occurred (days after

5

a

5
2 12, 45

a

1

implant)

21, 50, 68, 77, 89

1, 4, 20, 21, 64

118
1 28
1 64

8

198483001 C Medtronic Confidential Composed:xxxx-xx-xx4 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxx
Printing instructions: doc#xxxxxx refer to ’Implant manuals’ row in the applicable table.

Table 2. Complications related to ICD system and/or implant procedure (all patients, N=300): multiple
complications. Data from GEM DR clinical study (approved Oct. 1998).

# of Patients

Complicationsa(total, including
single complications)

Atrial lead dislodgement
Pneumothorax
Ventricular lead dislodgement
Hematoma
Respiratory failure

a

Complications are adverse eventsthat required invasive intervention. Complications that occurred in only
one patient are listed following the table. Some patients had more than one type of adverse event.

Single complications – Each of the following was observed once in one patient in the 300 patient clinical
study: Atrial oversensing/undersensing; Failure to capture ventricle; Inappropriate ventricular detection;
Increased pulse width threshold (atrium); Infection; and Protrusion under skin.

Table 3. Observations related to ICD system and/or implant procedure (all patients, N=300): multiple
observations. Data from GEM DR clinical study (approved Oct. 1998).

24 8.0% 31 0.45

13 4.3% 13 0.19

5
3 1.0% 3 0.04
2 0.7% 2 0.03
2 0.7% 2 0.03

Patients

Observationsa(total, including single
observations)

Incisional pain
Inappropriate ventricular detection
Patient Alert tone triggered
Atrial oversensing/undersensing
Hematoma
Atrial fibrillation/flutter
Incessant ventricular tachyarrhythmia
Ecchymosis
CHF/CHF exacerbation
Increased DFT
Ventricular oversensing
Inadequate pace/sense measurements

(atrium)
Increased pacing threshold
Infection

% of

Patients # of Events

1.7%

# of

% of

Patients

Events

134 44.7% 189 2.74

66 22.0% 67 0.97
23 7.7% 29 0.42
11 3.7% 14 0.20
10 3.3% 11 0.16

7

2.3%
6 2.0% 6 0.09
6 2.0% 6 0.09
4 1.3% 4 0.06
3 1.0% 4 0.06
3 1.0% 3 0.04
3 1.0% 3 0.04
2 0.7% 2 0.03

2 0.7% 4 0.06
2 0.7% 2 0.03

# of

5

7

Events per

Patient-Year

0.07

Events per

Patient-Year

0.10

9

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxx
Printing instructions: doc#xxxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 3. Observations related to ICD system and/or implant procedure (all patients, N=300): multiple
observations. Data from GEM DR clinical study (approved Oct. 1998). (continued)

# of

Pacemaker mediated tachycardia
Palpitations

a

Observations are adverse eventsthat did not require invasive intervention. Observations that occurred in
only one patient are listed following the table. Some patients had more than one type of adverse event.

Single observations – Each of the following was observed once in one patient in the 300 patient clinical
study: Awareness of ventricular pacing; Bronchitis; Cardiogenic shock; Cellulitis; Cut in outer lead insulation
of 6940 lead during repositioning; Delayed wound healing; Dizziness; Failure to defibrillate/cardiovert;
Fatigue; Fever;Frequent spontaneous SVTs; Generator migration; Inadequate pace/sense measurements
(ventricle); Insomnia; Lethargy; Multisystem failure; Near syncope; Pericardial effusion; Pneumothorax;
Pulmonary edema; Respiratory failure; Subclavian vein thrombosis; and VF therapy delivered despite
spontaneous episode termination.

Patients

% of

Patients

2 0.7% 2 0.03
2 0.7% 2 0.03

# of

Events

Events per

Patient-Year

5.2 Potential adverse events

Adverse events in alphabetical order, including those reported in Table 2 and Table 3, associated with
ICD systems include:

Acceleration of arrhythmias (caused by ICD) Air embolism

•

Bleeding

•

Chronic nerve damage

•

Erosion

•

Excessive fibrotic tissue growth

•

Extrusion

•

Fluid accumulation

•

Formation of hematomas or cysts

•

Inappropriate shocks

•

Infection

•

Keloid formation

•

Lead abrasion and discontinuity

•

Lead migration/dislodgment

•

Myocardial damage

•

Pneumothorax

•

Potential mortality due to inability to defibrillate or pace

•

Shunting current or insulating myocardium during defibrillation

•

Thromboemboli

•

Venous occlusion

•

Venous or cardiac perforation

•

Patients susceptible to frequent shocks despite antiarrhythmic medical management could develop
psychological intolerance to an ICD system that might include the following: Dependency; Depression; Fear
of premature battery depletion; Fear of shocking while conscious; Fear that shocking capability maybe lost;
Imagined shocking (phantom shock).

10

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx refer to ’Implant manuals’ row in the applicable table.

6 Clinical studies

Clinical studies were not performed on the Marquis
and the GEM DR, the GEM DR implant study was usedto support the Marqui
DR system (approved October 1998) involved an acute study and an implant study.

6.1 Acute study

The study was conducted in 62 patients undergoing ICD implantation or cardiac electrophysiology (EP)
study using an external device that contained the GEM DR ICD dual and single chamber tachyarrhythmia
detection algorithms.

Patients studied – The patients (44 M / 18F) had a mean age of 65.7 (range 33 – 87) years, anda mean left
ventricular ejection fraction of 36.8% (range 10 – 70%) (n=37). Arrhythmia histories included non-sustained
VT (24%), atrial fibrillation (19%), VT (18%) (non-exclusive).

Methods – The study evaluatedthe appropriateness of dual chamber sensing and tachyarrhythmiadetection
during induced and simulated cardiac arrhythmias. Arrhythmias (VT, VF, or SVT) were induced in 48 patients
and the episode records evaluated for relative sensitivity and incremental specificity.

Results – In the acute study, the GEM DR dual chamber detection algorithm (PR Logic Criteria for SVT
discrimination) demonstrated relative sensitivity (Table 5) of 98.5% [95% confidence interval of 89.9 – 99.8%]
and incremental specificity (Table6) of 77.4% [63.7 – 87.0%], compared to the GEM DR single chamber
detection algorithm. No adverse interactions between sensing, pacing and detection were observed. No
adverse events occurred during the study.

6.2 Implant study

This was a non-randomized, prospective study of 300 patients implanted with the GEM DR in the U.S.,
Europe, Canada and Australia. Most (295 patients) also received a Model 6940 CapSure Fix lead. The
mean implant duration was 2.8 months (range 0 to 5.3 months), with a cumulative implant duration of
828 device months.

Patients studied – The patients (238 M / 62 F) had a mean age of 63.5 (range 13 to 90) years and a left
heart ventricular ejection fraction of 37.5% (10% to 82%). The primary indications for implant included
ventricular arrhythmias (47%), ventricular arrhythmiasand sudden cardiac death (34%) and sudden cardiac
death (17%). Cardiovascular history included coronary artery disease and myocardial infarction (59%),
dilated cardiomyopathy (30%), congestive heart failure (26%) and hypertension (26%) (non-exclusive).

Methods – The primary objective was to demonstrate unanticipated device related effect
survival greater than 90% (lower confidence interval) at three months post-implant. Patients underwent
standard ICD implantation and were evaluated at one month and three months post-implant. The implant
criterion was DFT ≤ 22 J by the binary search method or 2 out of 2 successful defibrillations at ≤ 24 J.
Pacing and sensing were evaluatedvia ambulatory monitoring of 51 patients. Activity sensor-driven pacing
was evaluated in 20 patients who completed an exercise test. The heart rates at rest and during exercise
were measured, and the physician reported whether or not the exertional rate2was acceptable for the
patient’s level of exercise(Table8). Spontaneous VT/VF episodes were evaluated for therapyeffectiveness
(Table 7), relative sensitivity (Table 5), and incremental specificity (Table6), using the ICD stored episode
records. Patient Alert tone identifiability was evaluated via telephone monitoring at two months post-implant.
Subthreshold (painless) lead impedance testing was performed at each visit.

II DR. Because of the similarity between the Marquis II DR

s II DR. Clinical study of the GEM

1

(UADRE) -free

1

Any “serious [incapacitating, life threatening, or fatal] unanticipated clinical event related to the ICD,”
excluding random component failure and device misuse.

2

At the end of stage 3 of the CAEP treadmill exercise challenge.

11

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Results – The implant study results are detailed in Table 4 through Table 8. Patient Alert tones were
correctly identified by the patient and clinician in 115 of the 119 patients tested (96.6% success [95%
confidence interval of 91.6 – 99.2%]). No unanticipated device-related effects (UADRE) were identified
by the clinical events committee. All pacing and sensing functions evaluated via ambulatory monitoring
performed as intended.

Table4. Implant study results from GEM DR clinical study (approved Oct. 1998).

Measure Results Successes (#) Patients (#)
Results at Implant

% of patients meeting implant criterion of DFT
≤ 22 J with initial lead system using binary
search protocol [95% confidence intervalb]

% of patients meeting implant criterion of 2/2
inductions at ≤ 24 J with initial lead system
[95% confidence intervalb]

91.9%

[88.0 – 95.8%]

88.0%

[81.8 – 94.1%]

171 186

95 108

Chronic Results

Overall survival at 3 months [95% confidence
intervala]

Complication-free survival at 3 months [95%
confidence intervala]

UADRE-free survival at 3 months [95%
confidence intervalb]

a

Estimated by the Kaplan-Meier method.

b

Estimated by the exact binomial method.

Table5. Relative detection sensitivity,per VT/VF episode: dual chamber algorithm relative to single chamber
algorithm, based on data from GEM DR clinical study (approved Oct. 1998).

Relative Sensitivitya(%)

94.7%

[89.5 – 97.3%]

92.0%

[88.3 – 94.6%]

100.0%

[95.5 – 100.0%]

285 300

276 300

117 117

Detections of VT/VF (#) by
dual chamber algorithm

b

Acute Study,n = 30c[95% c.i.] 98.5% [89.9 – 99.8%] 67/ 68e(98.5%)
Implant Study,n = 66d[95% c.i.] 99.8% [99.2 – 99.9%] 795 / 797e(99.7%)

a

As adjusted for multiple episodes within a patient, based on the Generalized Estimating Equations
Model with exchangeable correlation.

b

Episode data recorded by the external device (acute study) or ICD memory (implant study), using the
GEM DR dual and single chamber detection algorithms.

c

30 patients with one or more induced VT/VF episodes.

d

66 patients with one or more spontaneous VT/VF episodes.

e

Detections of VT/VF episodes by the single chamber algorithm are stated as the denominator.

12

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B 2,Cxxxx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table6. Incremental detection specificity,per VT/VF episode: dual chamber algorithm relative to single
chamber algorithm based on data from GEM DR clinical study (approved Oct. 1998).

Discrimination of non-VT/VF
(#) by dual chamber

Incremental Specificitya(%)

algorithm

b

Acute Study,n = 32c[95% c.i.] 77.4% [63.7 – 87.0%] 43/ 60e(71.7%)
Implant Study,n = 42d[95% c.i.] 63.0% [49.0 – 75.1%] 212 / 295e(71.9%)

a

As adjusted for multiple episodes within a patient, based on the Generalized Estimating Equations
Model with exchangeable correlation.

b

Episode data recorded by the external device (acute study) or ICD memory (implant study), using the
GEM DR dual and single chamber detection algorithms.

c

32 patients with one or more induced SVT episodes.

d

42 patients with one or more spontaneous SVT episodes.

e

Detections of non-VT/VF episodes by the single chamber algorithm are stated as the denominator.

Table7. Spontaneous episode termination effectiveness,per episode based on data from GEM DR clinical
study (approved Oct. 1998).

Episodes

Effectivenessa(%) VT/VF Episodes (#)

Implant Study,n = 64
[95% c.i.]

a

As adjusted for multiple episodes within a patient, based on the Generalized Estimating Equations Model
with exchangeable correlation. The unadjusted results are essentially the same.

b

64 patients with one or more spontaneous VT/VF episodes.

b

99.1% [96.8 – 99.8%]

1153 1147

Successfully
Terminated (#)

6.2.1 Rate response
Methods – Clinical studies were not performed on the Marquis II DR. Because the same accelerometer-based

rate reponse feature is used by both the Marquis
(approved August 1999) was used to support the Marquis
centers worldwide, was a prospective evaluation of the rate response feature of the Sigma 300 DR
pacemaker. Patient data were collected at implant, pre-discharge, one month, three months,and six months
post-implant.

Objective – Rate response operation was evaluated to demonstrate that increases in pacing rates are
concurrent with increases in workload. Patients were evaluated utilizing a modified version of the Minnesota
Pacemaker Response Exercise Protocol (M-PREP)3at their one month visit. Evaluation of rate response
performance was conducted using the Metabolic Chronotropic Response model described by Wilkoff as
applied by Kay4. Valid data collected from patients thatperformed the exercise per protocol forat least three
minutes were included in the analysis.

Description of Patients – A total of 67 patients were enrolled and received an implanted pacemaker. The
mean age was 67.2 years (range: 19.5 to 85.2 years). Patientsmet the indications for dual chamber pacing:
atrial fibrillation/flutter in 23 patients and normal AV conduction in 13 patients (patients could have more
than one indication). Mean duration of implant was 3.8 months with a range of 0 to 6.9 months and a
total experience of 257 patient months.

3

Benditt, David G.M., Editor,Rate Adaptive Pacing, Blackwell Scientific Publications,Boston. 1993:63-65.

4

Kay, Neal G., Quantitation of Chronotropic Response: Comparison of Methods for Rate-Modulating
Permanent Pacemakers. JACC. Dec 92;20(7):1533-41.

II DR and Sigma 300 DR, the Sigma 300 DR clinical study

II DR. This study, conducted at 17 investigational

13

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx refer to ’Implant manuals’ row in the applicable table.

Results of the Study – The rate response clinical study was not performed on the Marquis
same accelerometer-based rate reponse feature is used by both the Marquis
Sigma 300 DR clinical study (approved August 1999) was used to support the Marquis

Table 8 provides the results of the clinical study. The performance of the rate response feature was found
to meet the study objective. Each of the 31 patients included in the analysis individually met the minimum

0.65 slope requirement.

II DR and Sigma 300 DR, the

Table8. Effectiveness Analysis based on Sigma 300 DR clinical study (approved Aug. 1999)

Mean Slope of M-PREP Rate
Response at 1 Month (n=31
patients)

1.02

a

All patients implanted (n=68 devices in 67 patients totaling 257 device-months).

Figure 1 shows the sensor-indicated rate (SIR) versus the Wilkoff-predicted heart rate achieved during the
M-PREP test at one month.

Observed 95% CI (Confidence
Interval)

[0.97, 1.06]

Performance Objective
Criterion: 95% CI (Confidence
Interval)

[0.65, 1.35]

II DR. Because the

II DR.

a

Figure 1. Rate Response Exercise Data based on Sigma 300 DR clinical study (approvedAug. 1999)

1

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

000.1

0.2

0.4

0.3

0.5

0.6

0.7

0.8

0.9

1

14

198483001 C Medtronic Confidential Composed:xxxx-xx-xx1:48

MedtronCRM B 2,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table9. Heart rate during activity sensor-drivenapacing, based on GEM DR clinical study (approved Oct.

1998). This table does not apply to Marquis

Heart Rate (Mean ± s.d.) 69.9 bpm ± 14.2 bpm 104 bpm ± 15.9 bpm

a

The type of sensor used by the GEM DR is a piezoelectric crystal. Because the Marquis
DR do not use the same type of rate response sensor, the GEM DR clinical study for rate response was
not used to support the Marquis II DR.

b

20 patients with activity sensor-driven pacing during an exercisetest. All 20 were judged by the physician
to have attained an adequate heart rate during exercise.

II DR.

Rate at Rest

b

n = 20

Rate During Exercise

b

n = 20

II DR and GEM

7 Patient selection and treatment

7.1 Individualization of treatment

Pectoral or abdominal implant site – Evaluatethe prospective patient’s size and activity level to determine

whether a pectoral or abdominal implant is suitable.
Exercise stress testing – If the patient’s condition permits, use exercise stress testing to:

Determine the maximum rate of the patient’s normal rhythm

•

Identify any supraventricular tachyarrhythmias

•

Identify exercise induced tachyarrhythmias.

•

The maximum exercise rate or the presence of supraventricular tachyarrhythmias may influence selection of
programmable parameters. Holter monitoring or other extended ECG monitoring also may be helpful.

Electrophysiologic (EP) testing – It is strongly recommended that candidates for ICD therapy have a
complete cardiac evaluation including EP testing. EP testing should identify the classifications and rates of
all the ventricular and atrial arrhythmias, whether spontaneous or induced during EP testing.

Drug resistant supraventricular tachyarrhythmias(SVTs) may initiate frequent unwanted device therapy.
A careful choice of programming options is necessary for such patients.

Antiarrhythmic drug therapy – If the patient is being treated with antiarrhythmic or cardiac drugs, the
patient should be on a maintenance drug dose rather than a loading dose at the time of device implantation.
If changes to drug therapy are made, repeated arrhythmia inductions are recommended to verify detection
and conversion. The device also may need to be reprogrammed.

Changes in a patient’s antiarrhythmic drug or any other medication that affects the patient’s normal cardiac
rate or conduction can affect the rate of tachyarrhythmias and/or effectiveness of therapy.

Direct any questions regarding the individualization of patient therapy to a Medtronic representative at
1-800-PCD-INFO (1-800-723-4636).

7.2 Specific patient populations

Pregnancy – If there is a need to image the device,care should be taken to minimize radiation exposure

to the fetus and the mother.
Nursing mothers – Although appropriate biocompatibility testing has been conducted forthis implant device,

there has been no quantitative assessment of the presence of leachables in breast milk.

Pediatric patients – This device has not been studied in patients younger than 13 years of age.
Geriatric patients – Most (67%) of the patients receiving the GEM DR ICD in clinical studies were over the

age of 60 years (see Section 6, “Clinical studies”, page 11).

15

198483001 C Medtronic Confidential Composed:

MedtronCRM B

xxxx-xx-xx 11:48

xxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

Handicapped and disabled patients – Special care is needed in using this device for patients using
electrical wheelchairs or other electrical (external or implanted) devices.

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

8 Patient counseling information

Physicians should consider the following points in counseling the patient about this device:

Persons administering CPR may experience the presence of voltage on the patient’s body surface

•

(tingling) when the patient’s device delivers a shock.
Advise patients to contact their physician immediately if they hear tones coming from their device.

•

Encourage patients to use identification cards (issued by Medtronic) and/or identification bracelets

•

documenting their device.

Discuss information in the Patient Manual (Restoring the Rhythms of Life and Model 9466 Patient Magnet
Instructions For Use) with patients before and after device implantation so they are fully familiar with
operation of the device. Advise patients how to obtain additional copies of the patient manuals.

9 Conformance to standards

This ICD was developed in conformance with all or parts of the following standards:

ISO 5841-3:1992(E), IS-1 IPG Connector Standard.

•

ISO 11318:1993(E), DF-1 Defibrillator Connector Standard.

•

EN45502 - Active Implantable Medical Devices, Part 1: General Requirements for Safety,Marking and

•

Information to be provided by the Manufacturer, August 1997.
prEN45502 - Active Implantable Medical Devices; Part 2-2: Particular Requirements for Active

•

Implantable Medical Devices Intended to Treat Tachyarrhythmia(Includes Implantable Defibrillators),
March 1998.

IEC 601-1, Medical Electrical Equipment: General Requirements for Safety.

•

This information should not be used as a basis of comparisons among devices since different parts of the
standards mentioned may have been used.

10 How supplied

The Model 7274 Marquis II DR device is packaged one per package in a sterile package.

11 Clinician use information

11.1 Physician training

Physicians should be familiar with sterile ICD implant procedure and familiar with follow-up evaluation and
management of patients with a defibrillator (or referral to such a physician).

11.2 Directions for use

Device operating characteristics should be verified at the time of implantation and recorded in the patient file.
Complete the Device Registration Form and return it to Medtronic as it provides necessary information for
warranty purposes and patient tracking.

The Marquis II DR Reference Manual, supplied with the XXXX software, provides complete programming
instructions and recommendations. Copies can be obtained by contacting the Medtronic representative, or
by calling 1-800-PCD-INFO (1-800-723-4636). The Reference Manual was last updated in

This Implant Manual was last updated xx-xxxx.

16

198483001 C Medtronic Confidential Composed

xxxxxxxxxxxx.

MedtronCRM B

xxxx-xx-xx 11:48

xxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

11.3 Maintaining device effectiveness

11.3.1 Device storage
FOR SINGLE USE ONLY. Do not resterilize and reimplant an explanted device. Medtronic has sterilized

the device with ethylene oxide prior to shipment. Resterilizing the device is necessary if the seal on the
sterile package is broken. Resterilization does not affect the “Use By” date because this date is based on
battery life and sterility.

Do not implant the device when:

It has been dropped on a hard surface from a height of 30 cm (12 in) or more because this could have

•

damaged ICD components;
Its storage package has been pierced or altered, because this could have rendered it non-sterile;

•

It has been stored or transported outside the environmental temperature limits of –18 to +55

•

131



F), as the device circuitry may have been damaged; or

Its “Use By” date has expired, because this can adversely affect devicelongevity or sterility.

•

11.3.2 Sterilization instructions

Do not resterilize the device or the torque wrench using an autoclave, gamma radiation, organic cleaning
agents (e.g., alcohol, acetone, etc.), or ultrasonic cleaners.

Should sterilization be required:

Repackage all items in a gas permeable container;

•

Use a validated ethylene oxide gas process;

•

Follow the manufacturer’soperation instructions so long as the maximum temperature does not exceed

•

55

C (131F), nor pressures of 15 psi;



Store the resterilized components for an appropriate period to permit aeration of ethylene oxide gas.

•



C (0 to

12 Patient information

Information for the patient is availablein a separate booklet, Restoring the Rhythms of Life, from Medtronic
(supplied with the device). To obtain additional copies, contact the Medtronic representative or call
1-800-PCD-INFO (1-800-723-4636). This information should be given to each patient with their device, and
offered to the patient on each return visit or as deemed appropriate.

Restoring the Rhythms of Life was developed using patient and clinician input to ensure that it is
understandable. Restoring the Rhythms of Life was last updated December 2001.

13 Implant procedure

Warnings:

Do not permit the patient to contact grounded equipment that could produce hazardous leakage current

•

during implantation. Resulting arrhythmia induction could result in the patient’s death.
The device is intended for implantation with Medtronic transvenous or epicardial defibrillation leads.

•

Transvenous (Endotak®series) or epicardial defibrillation leads manufactured by Guidant Corporation
can also be used. No claims of safety and efficacy can be made with regard to other non-Medtronic
acutely or chronically implanted lead systems.

Lead or Active Can electrodes in electrical contact during a high voltage therapy could cause current

•

to bypass the heart, possibly damaging the device and leads. While the device is connected to the
leads, make sure that no therapeutic electrodes, stylets, or guidewires are touching or connected by
an accessory low impedance conductive pathway. Move objects made from conductive materials (for
example, an implanted guidewire) well away from all electrodes before a high voltageshock is delivered.

17

198483001 C Medtronic Confidential Composed:XXXX-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx refer to ’Implant manuals’ row in the applicable table.

13.1 Pre-operative programming

Check the “Use By” date printed on the package. Do not implant the device after the “Use By” date, because
the battery’s longevity could be reduced.

Before opening the sterile package, prepare the ICD for implant as follows:

1. Interrogate the ICD and print a full summary report.

2. Confirm that the battery voltage is at least 3.0 V at room temperature.
If the device has been exposedto lower temperatures or has delivered a recent high voltage charge, the

battery voltage will be temporarily lower.

5

3. Set the ICD internal clock.

4. Perform a manual capacitor formation as follows:

Dump any charge on the capacitors.

•

Perform a test charge to full energy.

•

Retrieve the charge data.

•

Do not dump the stored charge. Allow it to dissipate, thus reforming the capacitors.

•

If the reported charge time is clinically unacceptable, contact a Medtronic representative.

•

5. Program the therapy and pacing parameters to values appropriate for the patient. Ensure that all
tachyarrhythmia detection is programmed off.

13.2 Testing lead operation

1. Implant endocardial leads according to the supplied instructions, unless suitable chronic leads6are
already in place. Do not use any lead with this device without first verifying connector compatibility. A
bipolar atrial lead with closely spaced pacing and sensing electrodes is recommended.

2. Verify appropriate sensing and an adequate pacing threshold margin (Table 10) using an implant support
instrument (PSA), according to its supplied instructions.

Table 10. Acceptable Implant Values

Measurements required Acute transvenous leads Chronic leads

R-wave amplitude ≥ 5 mV ≥ 3 mV
P-wave amplitude ≥ 2 mV ≥1 mV
Slew rate ≥ 0.5 V/s (atrial)

Capture threshold (0.5 ms pulse
width)

V. Defib. impedance

a

≥ 0.75 V/s (ventricular)
≤ 1.5 V (atrial)
≤ 1.0 V (ventricular)



20 - 200

b

≥ 0.3 V/s (atrial)
≥ 0.5 V/s (ventricular)
≤ 3.0 V (atrial)
≤ 3.0 V (ventricular)

5

Use the Quick Look screen to verify the voltage.

6

Chronic leads are leads implanted for 30 days or more.

18

198483001 C Medtronic Confidential Composed:xxxx-xx-xx1:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 10. Acceptable Implant Valuesa(continued)

Measurements required Acute transvenous leads Chronic leads

SVC (HVX) Defib. impedance
Defibrillation threshold

c

20 - 200

d



≤ 20 J (two consecutive) or

b

≤ 18 J (binary search)

a

The measured pacing lead impedance is a reflection of measuring equipment and lead technology. Refer
to the lead technical manual for acceptable impedance values.

b

Chronic leads are leads implanted for 30 days or more.

c

This measurement only applies if a supplementary electrode is connected to the SVC (HVX) port.

d

If a two-electrode system fails to meet the implant criterion, a third electrode can be added using the
SVC port.

13.3 Connecting leads to the implanted device

Warning: Loose lead connections may result in inappropriate sensing and failure to deliver necessary

arrhythmia therapy.
Caution: Use only the torque wrench supplied with the device. It is designed to prevent damage to the

device from overtightening a setscrew.
For easier lead insertion, insert the ventricular IS-1 leg before the other legs.

Table 11. Lead Connections

Device Port Connector Type Software Name

SVC DF-1 HVX
RV DF-1 HVB
Can n/a HVA, Can
V IS-1 bipolar
A IS-1 bipolar

Figure 2. Lead connections

A

V

SVC

RV

13.3.1 Lead connection procedure

1. Insert the torque wrench into the appropriate setscrew.
a. If the port is obstructed, retract the setscrew to clear it. Takecare not to disengage the setscrew

from the connector block.

b. Leave the torque wrench in the setscrew until the lead is secure. This allows a pathway for venting

trapped air when the lead is inserted.

19

198483001 C Medtronic Confidential Composed: 2xxxx-xx-xx 11:48

MedtronCRM B,C xxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

2. Push the lead or plug into the connector port until the lead pin is clearly visible in the pin viewing area.
No sealant is required, but sterile water may be used as a lubricant.

3. Tighten the setscrew by turning clockwise until the torque wrench clicks.

4. Tuggently on the lead to confirm a secure fit. Do not pull on the lead until all setscrews have been
tightened.

5. Repeat these steps for each lead.

Figure 3. Inserting a lead into the device

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

b

a

2

1

3

1 Lead
2 Setscrew block is located behind grommet
3 Tip of lead extends past setscrew block

13.4 Defibrillation threshold testing

Warning: Ensure that an external defibrillator is charged for a rescue shock.

1. Place the programming head over the ICD, start a patient session, and interrogate the device, if you
have not already done so.

2. Observe the Marker Channel annotations to verify that the ICD is sensing properly.

3. Conduct a manual Lead Impedance Test to verify the defibrillation lead connections. Performthis test
with the ICD in the surgical pocket and keep the pocket very moist. If the impedance is out of range,
perform one or more of the following tasks:

Recheck lead connections and electrode placement.

•

Repeat the measurement.

•

Inspect the bipolar EGM for abnormalities.

•

Measure the defibrillation impedance with a manual test shock.

•

4. Program the ICD or support instrument to properly detect VF with an adequate safety margin (1.2 mV
sensitivity).

20

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

5. Program the defibrillation parameters to the desired settings to be tested.

6. Induce and terminate VF using the ICD or support instrument and the implanted lead system (Table10).
Proper post-shock sensing must be observed.

13.5 Placing the device

Cautions:

If no SVC electrode is implanted, the pin plug provided with the device must be secured in the SVC port.

•

Program tachyarrhythmia detection Off before closing.

•

13.5.1 Placing the device procedure

1. Ensure that each lead pin or plug is fully inserted into the connector block and that all setscrewsare tight.

2. Coil any excess lead length beneath the device. Avoid kinks in the lead conductors.

3. Implant the device within 5 cm of the skin. This position optimizes the ambulatory monitoring operations.

4. Suture the device securely within the pocket to minimize post-implant rotation and migration of the
device. Use a normal surgical needle to penetrate the suture holes.

Figure 4. Suture holes

13.6 Programming

1. After closing the pocket, program detection On. Program ventricular tachyarrhythmiatherapies On
as desired.

2. Do not enable the Other 1:1 SVTs PR Logic detection criterion until the atrial lead has matured
(approximately one month post implant).

3. If external equipment was used to conduct the defibrillation efficacy tests, perform a final VF induction
and allow the implanted system to detect and treat the arrhythmia.

13.7 Replacing an old ICD

1. Program all tachyarrhythmia detection Off.

2. Dissect the leadsand the device freefrom the pocket. Be careful not to nickor breach the leadinsulation.

3. Loosen each setscrew, and gently retract the lead from the connector block.

4. Remove the ICD from the surgical pocket.

5. If the connector pin of any implanted lead shows signs of pitting or corrosion, replace the implanted
lead with a new lead. The damaged lead should be discarded and replaced to assure the integrity
of the device system.

21

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxx-xx-xx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

6. Measure sensing, pacing, and defibrillation efficacy using the replacement ICD or an implant support
instrument.

7. Evaluate the defibrillation efficacy of the replacement system.

You mayneed an adaptor that will enable connection of the device to the implanted leads (Table13, page 23).

14 Feature summary

See the “Shipped” column of the tables in Section 15.5, page 26, for a list of which features are enabled
at shipping.

14.1 Tachyarrhythmia operations

Anti-tachycardia pacing therapies – Deliver rapid pacing pulses to overdrive and terminate the detected

arrhythmia.
Auto-adjusting sensitivity – Automatically adjusts the sensitivity thresholds following certain paced and

sensed events to reduce the incidence of T-wave sensing and cross-chamber sensing.
Committed defibrillation therapy – Up to six automatic defibrillation shocks to treat VF.Therapy is delivered

asynchronously if synchronization fails. Tilt is fixed at 50%.
High rate timeout – Disables supplementary SVT detection criteria when a ventricular episode exceeds a

programmed duration.
PR Logic SVT discrimination – Withholds inappropriate ventricular detection during episodes of rapidly

conducted supraventricular tachycardia(SVTs), using pattern and rate analysis to identify different SVTs.

Reconfirm VF – Aborts the first defibrillation therapy if synchronization fails.
Stability criterion – Withholds VT detection for rapid rhythms (in the VT detection zone) with irregular

intervals.
Synchronized cardioversion therapy – Up to six shocks to treat VT or FVT. Tilt is fixed at 50% for

all ventricular cardioversion.

14.2 Pacing operations

Mode Switch – Prevents tracking of paroxysmal atrial tachycardias by switching from a tracking mode to

a non-tracking mode.
Non-Competitive Atrial Pacing (NCAP) – Delays an atrial pace from falling within the atrium’s relative

refractory period.
Pacemaker-Mediated Tachycardia (PMT) Intervention – Provides automatic detection and interruption

of pacemaker-defined PMTs.
Premature Ventricular Contraction (PVC) response – Extends the atrial refractory period following a PVC

to promote dual chamber synchrony and cycle length regularity.
Rate Adaptive AV (RAAV) – Varies the Paced AV (PAV) and Sensed AV(SAV) intervals as the heart rate

increases or decreases during dual chamber operation.
Rate Responsive Pacing – Variesthe pacing rate in response to the patient’s physicalmotion as detected

by an activity sensor.
Ventricular Rate Stabilization – Adjusts the ventricular escape interval dynamically to eliminate abrupt

variations in the cycle length.
Ventricular Safety Pacing – Prevents inappropriate inhibition of ventricular pacing caused by crosstalk or

ventricular oversensing.

22

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

14.3 Monitoring operations

Cardiac Compass trends – Plots long term trends in heart rhythm and device status for up to 14 months.
Episode data and EGM storage – Records diagnostic quality electrogram during every detected arrhythmia

episode.
Flashback memory – Stores dual chamber intervals for severalminutes prior to recent detected arrhythmia

episodes, and prior to interrogation.
Holter telemetry – Allows the implanted device to continuously transmit an EGM with marker telemetry,

with or without applying the programming head, for up to 46 hours.
Patient Alert – Notifies the patient with an audible tone if the device identifies any of the programmed

or automatic alert conditions.

15 Product specifications

15.1 Physical specifications (nominal)

Table 12. ICD physical characteristics

Volume
Mass

b

H x W x D
Surface area of device can
Radiopaque ID

a

Measurements are nominal values based on CAD (computer aided design) model measurements,
and are rounded to the nearest unit.

b

Grommets may protrude slightly beyond the can surface.

c

Engineering series number follows the radiopaque code.

c

15.1.1 Materials

The device presents the following materials into contact with human tissue: titanium; polyurethane; silicone
rubber. These materials have been successfully tested for the ability to avoid biological incompatibility. The
device does not produce an injurious temperature in the surrounding tissue.

15.1.2 Lead compatibility
Table 13. Compatible adaptors

Port Primary Lead Lead Adaptor

RV, SVC DF-1

a

A, V IS-1abipolar 5866-24M for 5 mm paired unipolar

a

DF-1 refers to the international standard ISO 11318:1993. IS-1 refers to ISO 5841-3:1992(E).

15.2 Replacement indicators

Battery voltage and messages about replacement status appear on the programmer display and on printed
reports. Table 14 lists the Elective Replacement Indicator (ERI) and the End of Life (EOL) conditions.

a

36 cc
75 g

68.3 mm x 50.8 mm x 13.9 mm

2

66 cm
PKC

6707 for 6.5 mm cardioversion/defibrillation lead

5866-24M for 5 mm bifurcated
5866-38M for IS-1 unipolar
5866-40M for Medtronic 3.2 mm low-profile

23

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

Table 14. Replacement indicators

Elective Replacement (ERI) ≤2.62 V
End of Life (EOL) 3 months after ERI

EOL indication – If the programmer indicates that the deviceis at EOL, replace the device immediately.
ERI date – The programmer displays the date when the battery reached ERI on the Quick Look and Battery

and Lead Measurements screens.
Post-ERI conditions – EOL device status is defined as three months followingan ERI indication assuming

the followingpost-ERI conditions: 100% DDD pacing at 60 ppm, 3 V,0.4 ms; 500
charges. EOL may be indicated before the end of three months if the device exceeds these conditions.

Temporary voltage decrease – The battery voltage temporarily decreases following a high voltage charge.
If a battery measurement is taken immediately after a high voltage charge, ERI or EOL indicator may be
displayed. However, this is a temporary status which will return to normal when the battery has recovered
from the charge.

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

pacing load; and six 30 J



15.3 Projected longevity

Longevity estimates are based on accelerated battery discharge data and device modeling at 60 ppm
pacing rate, with:

2.5 V pacing pulse amplitude, 0.4 ms pacing pulse width, and 30 J delivered therapy energy (see

•

Table 15)
3 V pacing pulse amplitude, 0.4 ms pacing pulse width, and 30 J deliveredtherapy energy (see Table 16)

•

This modelassumes default automatic capacitorformation setting, as described inthe Marquis II DR Reference
manual. As a guideline, each full energy charge decreases device longevity by approximately 24 days.

Device longevity is affected by how certain features are programmed, such as EGM pre-storage. For more
information, see the Optimizing longevity chapter of the Marquis II DR Reference manual.

Considerations for using EGM pre-storage – When the EGM pre-storage feature is programmed off, the
device starts to store EGM following the third tachyarrhythmia event and also provides up to 20 seconds of
information before the onset of the tachyarrhythmia, including:

AA and VV intervals

•

Marker Channel

•

interval plot Flashback

•

When the EGM pre-storage feature is programmed on, the device also collects up to 20 seconds of EGM
information before the onset of the arrhythmia.

In a patient who uniformly repeats the same onset mechanisms, the greatest clinical benefit of pre-onset
EGM storage is achieved after a few episodes are captured. To maximize the effectiveness of the EGM
pre-storage feature and optimize device longevity, consider these programming options:

Turn pre-storage on to capture possible changes in the onset mechanism following significant clinical

•

adjustments, for example, device implant, medication changes, and surgical procedures.
Turn pre-storage off once you have successfully captured the information of interest.

•

24

198483001 C Medtronic Confidential Composed:

MedtronCRM B

xxxx-xx-xx 11:48

,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx refer to ’Implant manuals’ row in the applicable table.

Table15. Projected longevity in years with 2.5 V pacing amplitude and 0.4 ms pulse width

Percent
pacing

0%

Maximum
energy charging

a

frequency

EGM pre-storagebDDD VVI DDD VVI

Semi-Annual Off

On

Quarterly Off

On

15%

Semi-Annual Off

On

Quarterly Off

On

50%

Semi-Annual Off

On

Quarterly Off

On

100%

Semi-Annual Off

On

Quarterly Off

On

a

Maximum energy charging frequency may include full energy therapy shocks or capacitor formations.

b

The data provided for programming EGM pre-storage on is based on a 6 month period (two 3-month
follow-up intervals) over the life of the device. Additional use of EGM pre-storage reduces longevity by
approximately 25% or 3 months per year.

500pacing
impedance

8.6 8.6 8.6 8.6

8.5 8.5 8.5 8.5

7.5 7.5 7.5 7.5

7.3 7.3 7.3 7.3

8.3 8.5 8.5 8.6

8.1 8.4 8.3 8.5

7.2 7.4 7.3

7.0 7.3 7.1 7.3

7.5

8.2 8.0 8.5

7.4 8.0 7.9 8.2

6.6 7.1 7.0 7.3

6.5 7.0 6.8 7.1

6.7

6.5

7.7 7.5

7.5

6.0 6.8 6.6 7.1

5.8 6.5 6.4 6.9

900pacing
impedance

7.5

8.1

7.3 8.0

Table16. Projected longevity in years with 3 V pacing amplitude and 0.4 ms pulse width

Percent
pacing

0%

15%

50%

Maximum
energy charging

a

frequency

Semi-Annual Off

Quarterly Off

Semi-Annual Off

Quarterly Off

Semi-Annual Off

Quarterly Off

EGM
pre-storage

On

On

On

On

On

500pacing
impedance

b

DDD VVI DDD VVI

8.6 8.6 8.6 8.6

8.5 8.5 8.5 8.5

7.5 7.5 7.5 7.5

7.3 7.3 7.3 7.3

8.1 8.5 8.4 8.6

8.0 8.3 8.2 8.4

7.1 7.3 7.3

6.9 7.2 7.1 7.3

7.2 8.0 7.8 8.3

7.0 7.8 7.6 8.1

6.4 7.0 6.8 7.2

900pacing
impedance

7.5

25

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table16. Projected longevity in years with 3 V pacing amplitude and 0.4 ms pulse width (continued)

Percent
pacing

Maximum
energy charging

a

frequency

EGM
pre-storage

On

100%

Semi-Annual Off

On

Quarterly Off

On

a

Maximum energy charging frequency may include full energy therapy shocks or capacitor formations.

b

The data provided for programming EGM pre-storage on is based on a 6 month period (two 3-month
follow-up intervals) over the life of the device. Additional use of EGM pre-storage reduces longevity by
approximately 25% or 3 months per year.

500pacing
impedance

b

DDD VVI DDD VVI

6.2 6.8 6.7 7.0

6.2 7.3 7.1 8.0

6.0 7.1 7.0

5.5

6.5 6.3 6.9

5.4 6.3 6.1 6.8

900pacing
impedance

7.7

15.4 Magnet behavior

Pacing mode as programmed
Pacing rate and interval as programmed
VF, VT, and FVT detection suspended
Patient Alert audible tones with programmable alerts enabled:

continuous tone (Test)

•

on/off intermittent tone (seek follow-up)

•

high/low dual tone (urgent follow-up)

•

with programmable alerts disabled:

no tone

•

high/low dual tone (urgent follow-up)

a

Rate response adjustments are suspended while a Patient Alert tone sounds.

b

Detection resumes if telemetry is established and the application software is running or it resumes after
the application software has started.

c

The Test tone does not sound if VF Detection/Therapy Off is the only alert enabled.

•

a

b

c

15.5 Functional parameters

Programmable parameters are determined by the software used in the programmer. Functional parameters
are measured at body temperature and 500
Parameter values are “typical” where no tolerance is stated.

If the programmer displays a message that an electrical reset has occurred, contact your Medtronic
representative.

load (brady parameters) and 75load (tachy parameters).



26

198483001 C Medtronic Confidential Composed:xxxx-xx-xx-14 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

15.5.1 Emergency settings
Table 17. Emergency parameters

Parameter Selectable values Default
Defibrillation

Energy 10, 11, …, 16, 18, 20, …, 30 J 30 J

a

Pathway

AX>B

—

Cardioversion

Energy 0.4, 0.6, …, 2, 3, 4, …, 16, 18, 20, …, 30 J 30 J
Pathway AX>B

—

Fixed burst

Pacing Interval
V. Pulse Amplitude

b

V. Pulse Width

VVI pacing

Pacing Mode VVI
Lower Rate
V. Sensitivity / A. Sensitivity as programmed
V. Pulse Amplitude

b

V. Pulse Width
V. Pace Blanking
Hysteresis Off
V. Rate Stabilization Off

a

If Active Can is Off, the HVA (Can) electrode is not used as part of the high voltage delivery pathway.

b

Peak pacing amplitude. When tested per CENELEC standard 45502-2-1, the measured
amplitude A depends upon the programmed amplitude Apand programmed pulse width Wp:
A = Apx [0.9 – (Wpx 0.145 ms-1)].

100, 110, …, 600 ms 350 ms
8 V

1.6 ms

—
—

—

70 ppm

6 V

1.6 ms
240 ms

—
—
—
—
—
—
—

15.5.2 Detection parameters
Table 18. Tachyarrhythmiadetection parameters

Parameter Programmable values Shipped Nominal Reset

VF Detection Enable On, Off Off On On
VF Interval
VF Initial NID 12/16, 18/24, 24/32,

VF Redetect NID 6/8, 9/12, 12/16, 18/24,

FVT Detection Enable Off, via VF, via VT Off Off Off
FVT Interval

a

a

240, 250, …, 400 ms 320 ms 320 ms 320 ms

30/40, 45/60, 60/80,
75/100, 90/120, 105/140,
120/160

21/28, 24/32, 27/36,
30/40

200, 210, …, 600 ms

18/24 18/24 18/24

12/16 12/16 12/16

— — —

27

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 18. Tachyarrhythmiadetection parameters (continued)

Parameter Programmable values Shipped Nominal Reset

VT Detection Enable On, Off, Monitor Off Off Off
VT Interval
VT Initial NID
VT Redetect NID
Stability
AFib / AFlutter
Sinus Tach
1:1 VT-ST Boundary
Other 1:1 SVTs
SVT Limit
High Rate Timeout Off, 0.75, 1, 1.25, 1.5, 2,

High Rate Timeout
Therapy

A. Sensitivity

V. Sensitivity

a

b

c

d

e

a

280, 290, …, 600 ms 400 ms 400 ms 400 ms
12, 16, …, 52, 76, 100 16 16 16

a

b,c

b,c

a

d,e

d,e

The measured intervals are truncated to a 10 ms multiple (e.g., 457 ms becomes 450 ms). The device
uses this truncated interval value when applying the programmed criteria and calculating interval
averages.
Double tachycardia (i.e. “VF/FVT/VT plus SVT”) detection is automatically enabled when any Dual
Chamber SVT criterion is enabled.

The device is shipped with the Sinus Tach and A.Fib / A.Flutter criteria off. However, when VT Detection
is set to On or Monitor, these parameters are set to On.
With a 40 ms sine2waveform (ventricular sensitivity) or a 20 ms sine2waveform (atrial sensitivity). When
using the CENELEC waveform, the rated sensing threshold value will be 1.5 times (ventricular) or 1.4
times (atrial) the rated sine2sensing threshold.
This setting applies to all sensing in this chamber for both tachyarrhythmiadetection and bradycardia
pacing operations.

4, 8, 12, …, 52 12 12 12
Off, 30, 40, …, 100 ms Off Off Off
On, Off Off Off Off
On, Off Off Off Off
35, 50, 66, 75, 85% 50% 50% 50%

b

On, Off Off Off Off
240, 250, …, 600 ms 320 ms 320 ms 320 ms

2.5, …, 5, 6, 7, …, 20,
22, 24, …, 30 min

Zone Appropriate, Skip
to VF Therapy

0.15, 0.3, 0.45, 0.6, 0.9,

1.2, 1.5, 2.1 mV

0.15, 0.3, 0.45, 0.6, 0.9,

1.2 mV

Off Off Off

Zone
Appropriate

0.3 mV 0.3 mV 0.3 mV

0.3 mV 0.3 mV 0.3 mV

Zone
Appro­priate

Zone
Appropriate

15.5.3 Therapy parameters
Table 19. Tachyarrhythmiatherapy parameters

Parameter Programmable values Shipped Nominal Reset

VF Therapy Status
VT Therapy Status
VT Therapy Type
FVT Therapy Status
FVT Therapy Type

a

On, Off On On On

a

On, Off None On None

a

CV, Burst, Ramp, Ramp+

a

On, Off None On None

a

CV, Burst, Ramp, Ramp+

— — —

— — —

28

198483001 C Medtronic Confidential Composed:xxxx-xx-xx1:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 19. Tachyarrhythmiatherapy parameters (continued)

Parameter Programmable values Shipped Nominal Reset
VF therapy (defibrillation) parameters

Energy

b,c

0.4, 0.6, …, 1.8, 2, 3, …, 16,
18, 20, …, 30 J

30 J 30 J 30 J

Pathway AX>B, B>AX AX>B AX>B AX>B
Confirm VF after initial

a,d

detection?

Cardioversion parameters

c

Energy

Pathway AX>B, B>AX

Burst therapy parameters

Initial # Pulses
R-S1 Interval (% R-R)

Interval Decrement
# Sequences
Smart Mode

a

a,f

Ramp therapy parameters

Initial # Pulses
R-S1 Interval (% R-R)

Interval Decrement
# Sequences
Smart Mode

a

a,f

Ramp+ therapy parameters

Initial # Pulses
R-S1 Interval (% R-R)

S1-S2 Interval (% R-R)

S2-SN Interval (% R-R)

# Sequences
Smart Mode

a

a,f

Yes, No Yes Yes Yes

0.4, 0.6, …, 1.8, 2, 3, …, 16,
18, 20, …, 30 J

1, 2, …, 15
50, 53, 56, 59, 63, 66, …,

84, 88, 91, 94, 97

a

0, 10, …, 40 ms
1, 2, 3, …, 10
On, Off

1, 2, …, 15
50, 53, 56, 59, 63, 66, …,

84, 88, 91, 94, 97
0, 10, …, 40 ms
1, 2, …, 10
On, Off

1, 2, …, 15
50, 53, 56, 59, 63, 66, …,

84, 88, 91, 94, 97
50, 53, 56, 59, 63, 66, …,

84, 88, 91, 94, 97
50, 53, 56, 59, 63, 66, …,

84, 88, 91, 94, 97
1, 2, …, 10
On, Off

—

—

—
—

—
—
—

—
—

—
—
—

—
—

—

—

—
—

30 J

AX>B

e —

6

e —

84

10 ms

e —

3
Off

g —

8

h —

91

10 ms
3
Off

3
75

69

66

5
Off

—

—

—

—

—
—
—

—
—

—

—

—
—

Shared therapy parameters

Progressive Episode

a

Therapies

On, Off Off Off Off

Active Can On, Off On On On

29

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 19. Tachyarrhythmiatherapy parameters (continued)

Parameter Programmable values Shipped Nominal Reset

V. Pulse Width

V. Amplitude

i

V. Pace Blanking
ATP Minimum Interval

a

This parameter does not apply to manual therapies.

b

For automatic therapy 3, 4, 5, or 6, energy must be at least 10 J.

c

Delivered energy based on a biphasic pulse into a 75
is ±0.25 J.

d

Applies only to the first VF therapy that is programmed On.

e

FVT Burst therapies have the following Medtronic nominal values: Initial # Pulses is 8, R-S1 Interval is
88%, and # Sequences is 1.

f

Smart Mode is only availablefor Therapies 1, 2, 3, and 4.

g

The nominal Initial # of Pulses for manual ramp therapy is 6.

h

The nominal R-S1 Interval for manual ramp therapyis 97%.

i

Peak pacing amplitude. When tested per CENELEC standard 45502-2-1, the measured
amplitude A depends upon the programmed amplitude Apand programmed pulse width Wp:
A = Apx [0.9 – (Wpx 0.145 ms-1)].

0.03, 0.06, 0.1, 0.2, …,

1.6 ms

0.5, 1, …, 4, 5, 6, 8 V 8.0 V 8.0 V 8.0 V
150, 160, …, 440 ms 240 ms 240 ms 240 ms
150, 160, …, 400 ms 200 ms 200 ms 200 ms

1.6 ms 1.6 ms 1.6 ms

load. For energy less than 1 J, tolerance



15.5.4 Bradycardia pacing parameters
Table 20. Bradycardia pacing parameters

Parameter Programmable values Shipped Nominal Reset

Pacing Mode DDDR, DDD, DDIR, DDI,

Lower Rate

Upper Tracking Rate
Upper Sensor Rate
Paced AV
Sensed AV
PVARP Varied, 150, 160, …,

A. Refractory

a

PVAB
A. Amplitude

b

A. Pulse Width

A. Sensitivity

c,d

A. Pace Blanking

AAIR, AAI, VVIR, VVI,
DOO, VOO,ODO

30, 35, 40, …, 60, 70,
75, …, 150 ppm

80, 85, …, 150 ppm 120ppm 120 ppm 120 ppm
80, 85, …, 150 ppm 120ppm 120 ppm 120 ppm
30, 40, …, 350 ms 180ms 180 ms 180 ms
30, 40, …, 350 ms 150ms 150 ms 150 ms

500 ms
150, 160, …, 500 ms 310 ms 310 ms 310 ms
100, 110, …, 310 ms 150 ms 150 ms 150 ms

0.5, 1, …, 3, 3.5, 4, 5, 6 V 3 V 3V 4 V

0.03, 0.06, 0.1, 0.2, …,

1.6 ms

0.15, 0.3, 0.45, 0.6, 0.9,

1.2, 1.5, 2 mV
150, 160, …, 250 ms 200 ms 200 ms 240 ms

DDD DDDR VVI

60 ppm 60 ppm 65 ppm

310 ms 310 ms 310 ms

0.4 ms 0.4 ms 0.4 ms

0.3 mV 0.3 mV 0.3mV

30

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 20. Bradycardia pacing parameters (continued)

Parameter Programmable values Shipped Nominal Reset

V. Amplitude
V. Pulse Width

V. Sensitivity

V. Pace Blanking

Post-Shock Pacing Parameters

A. Amplitude
A. Pulse Width

V. Amplitude
V. Pulse Width

b

c,d

0.5, 1, …, 3, 3.5, 4, 5, 6 V 3 V 3 V 6 V

0.03, 0.06, 0.1, 0.2, …,

1.6 ms

0.15, 0.3, 0.45, 0.6, 0.9,

1.2 mV

0.4 ms 0.4 ms 1.6 ms

0.3 mV 0.3 mV 0.3mV

150, 160, …, 440 ms 200 ms 200 ms 240 ms

b

b

0.5, 1, 1.5, …, 4, 5, 6, 8 V 4 V 4 V 4 V

0.03, 0.06, 0.1, 0.2, …,

1.6 ms

1.6 ms 1.6 ms 1.6 ms

0.5, 1, 1.5, …, 4, 5, 6, 8 V 6 V 6 V 6 V

0.03, 0.06, 0.1, 0.2, …,

1.6 ms

1.6 ms 1.6 ms 1.6 ms

Mode Switch Parameters

Enable On, Off Off On Off
A. Detect Rate 120, 125, …, 175 bpm 175 bpm 175 bpm 175 bpm

Rate Response Pacing Parameters

Rate Response
Activity Threshold Low,Medium Low, Medium

Activity Acceleration

1, 2, …, 10

High, High
15, 30, 60 s 30 s 30 s 30 s

7 7 7
Medium Low Medium Low Medium

Low

Activity Deceleration Exercise, 2.5, 5, 10 min 5 min 5 min 5 min

Rate Adaptive AV Parameters

Enable On, Off On On On
Start Rate 50, 55, …, 145 bpm 60 bpm 60 bpm 60 bpm
Stop Rate 55, 60, …, 150 bpm 120bpm 120 bpm 120 bpm
Minimum PAV
Minimum SAV

30, 40, …, 350 ms 140ms 140 ms 140 ms
30, 40, …, 350 ms 110ms 110 ms 110 ms

Additional Pacing Features

Non-Comp Atrial Pacing

Enable On, Off On On On
Interval

Single Chamber
Hysteresis

200, 250, …, 400 ms 300 ms 300 ms 300 ms
Off, 30, 40, …, 80 bpm Off Off Off

V. Rate Stabilization

V. Rate Stabilization On, Off Off Off Off
V. Rate Stabilization

Minimum Interval

500, 550, …, 900 ms 500 ms 500 ms 500 ms

31

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#

xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 20. Bradycardia pacing parameters (continued)

Parameter Programmable values Shipped Nominal Reset

V. Rate Stabilization
Interval Increment

50, 60, …, 400 ms 150ms 150 ms 150 ms

PMT Intervention On, Off Off Off Off
PVC Response On, Off On On On
V. Safety Pacing On, Off On On On

a

PVABis the minimum value that PVARP is shortened to, under sensor-varied PVARP operation. Atrial
events that fall within the PVAB are ignored by the Mode Switch, NCAP, PVC Response, and PMT
Intervention features.

b

Peak pacing amplitude. When tested per CENELEC standard 45502-2-1, the measured
amplitude A depends upon the programmed amplitude Apand programmed pulse width Wp:
A = Apx [0.9 – (Wpx 0.145 ms-1)].

c

With a 40 ms sine2waveform (ventricular sensitivity) or a 20 ms sine2waveform (atrial sensitivity). When
using the CENELEC waveform, the rated sensing threshold value will be 1.5 times (ventricular) or 1.4
times (atrial) the rated sine2sensing threshold.

d

This setting applies to all sensing in this chamber,for both tachyarrhythmia detection and bradycardia
pacing operations.

15.5.5 System maintenance parameters
Table 21. System maintenance parameters

Parameter Programmable values Shipped Nominal Reset

Automatic Capacitor
Formation Interval

Patient Alert time enter time in hours and

Auto, 1, 2, …, 6 months Auto

minutes

a

8:00 am

Auto Auto
—

8:00 am

Impedance patient alerts

A. Pacing lead On, Off Off On Off

Minimum Threshold
Maximum Threshold

200, 300, 400, 500



1000, 1500, 2000, 3000



200



3000



200
3000





200
3000





V. Pacing lead On, Off Off On Off

Minimum Threshold
Maximum Threshold

200, 300, 400, 500



1000, 1500, 2000, 3000



200



3000



200
3000





200
3000





V. Defibrillation lead On, Off Off On Off

Minimum Threshold
Maximum Threshold

SVC (HVX) Defibrillation
lead

Minimum Threshold
Maximum Threshold

Lead impedance alert
urgency

20, 30, 40, 50
100, 130, 160, 200





On, Off Off On Off

20, 30, 40, 50
100, 130, 160, 200





Low, High

20
200

20
200

—









20
200

20
200
Low









20
200

20
200

—









32

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 21. System maintenance parameters (continued)

Parameter Programmable values Shipped Nominal Reset

Low Battery Voltage ERI
patient alert

Excessive Charge Time
ERI patient alert

Number of Shocks
Delivered in an Episode
patient alert

Number of Shocks
threshold

All Therapies in a
Zone Exhausted for
an Episode patient alert

VF Detection/Therapy

b

Off

a

Automatic Capacitor Formation is disabled until VF Detection is set to On for the first time.

b

When this alert is turned on, it does not sound when a magnet is applied unless VF detection or more
than two VF therapies are turned off.

Off, On-Low,On-High Off On-Low Off

Off, On-Low,On-High Off On-Low Off

Off, On-Low,On-High Off On-Low Off

1, 2, …, 6 3 3 3

Off, On-Low,On-High Off On-Low Off

Off, On-High On-High On-High On-High

15.5.6 Data collection parameters
Table 22. Data collection parameters

Parameter Programmable values Shipped Nominal Reset

EGM Channel 1
Source

EGM Channel 1
Range

EGM Channel 2
Source

EGM Channel 2
Range

Store EGM Channel

b

1?
Store EGM Channel2Yes (fixed)

Store EGM during
charging?

Store EGM before
tachycardia starts?

Device Date/Timec(enter time and date)

Can to HVB, Can to Vring, Can
to Aring, Vtip to HVB, Vtip to
Vring, Atip to Vring, Atip to
Aring, Can to HVX,aHVB to

a

HVX

Atip to
Aring

Atip to Aring Atip to

Aring

±2, ±4, ±8, ±16 mV ±8 mV ±8 mV ±8 mV

Can to HVB, Can to Vring, Vtip
to HVB, Vtip to Vring, Can to
HVX,aHVB to HVX

a

Vtip to
Vring

Vtip to Vring Vtip to

Vring

±2, ±4, ±8, ±16 mV ±8 mV ±8 mV ±8 mV

Yes, No Yes Yes Yes

— — —

Yes, No Yes Yes Yes

Yes, No No No No

— — —

33

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 22. Data collection parameters (continued)

Parameter Programmable values Shipped Nominal Reset

Premature Event
Threshold

Holter Telemetry
Duration

a

An SVC lead must be present for this configuration.

b

Both channels are available as real-time telemetered signals, regardless of this setting.

c

The time stamp on episode records and other stored data is determined by the device’sdate/time clock.

56, 59, 62, 66, 69, …, 84, 88,
91, 94, 97%

Off, 0.5, 1, 2, 4, 8, 16, 24, 36,
46 hours

69% 69% 69%

Off Off Off

15.5.7 System test and EP study parameters
Table 23. System test and EP study parameters

Parameter Selectable values Default
Pacing threshold test parameters

Test Type Pulse Width - Auto Dec, Manual Pulse Width - Auto Dec
Chamber Atrium, Ventricle Ventricle
Mode (atrial test)
Mode (ventricular test)
Lower Rate
AV Delay
V. Amplitude
V. Pulse Width
V. Pace Blanking
A. Amplitude
A. Pulse Width
A. Pace Blanking
PVARP

EGM Amplitude test parameters

Mode
AV Delay
Lower Rate

a

AAI, DDI, DDD DDD

a

VVI, DDI, DDD VVI
30, 35, …, 60, 70, 75, …, 150 ppmc90 ppm

d

30, 40, …, 350 ms 150 ms

0.5, 1, …, 4, 5, 6 V 3 V

0.03, 0.06, 0.1, 0.2, …, 1.6 ms 0.4 ms

d

150, 160, …, 440 ms 200 ms

0.5, 1, …, 4, 5, 6 V

0.03, 0.06, 0.1, 0.2, …, 1.6 ms 0.4 ms
150, 160, …, 250 ms 200 ms
150, 160, …, 500 ms 310 ms

e

ODO, AAI, VVI, DDI, DDD
30, 40, …, 350 ms 250 ms
30, 35, …, 60, 70, 75, …, 120 ppm

b —

3 ms

—

b

b

b

b

b

b

b

b

b
b

T-Shock induction parameters

#S1
S1S1
Delay
Energy

2, 3, …, 8 8
300, 310, …, 2000 ms 400 ms
50, 60, …, 600 ms 310 ms

0.4, 0.6, …, 1.8, 2, 3, …, 16, 18,
20, …, 30 J

0.6 J

Pathway AX>B, B>AX AX>B
Waveform Monophasic, Biphasic Monophasic
Pulse Amplitude

d

8 V (fixed)

—

34

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,xxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 23. System test and EP study parameters (continued)

Parameter Selectable values Default

Pulse Width 1.6 ms (fixed)

—

Enable Enabled, Disabled Disabled
Resume at Deliver Enabled, Disabled Enabled

50 Hz Burst Induction Parameters

Interval 20ms (fixed)
Pulse Amplitude
Pulse Width

d

0.5, 1, …, 4, 5, 6, 8 V 8 V

0.03, 0.06, 0.1, 0.2, …, 1.6 ms 1.6 ms

—

Resume at Burst Enabled, Disabled Enabled

Manual Burst Induction Parameters

Chamber Ventricle, Atrium Ventricle
Interval
Pulse Amplitude
Pulse Width

d

100, 110, …, 600 ms 600 ms

0.5, 1, …, 4, 5, 6, 8 V 4 V

0.03, 0.06, 0.1, 0.2, …, 1.6 ms 0.5 ms
Resume at Burst Enabled, Disabled Enabled
VVI Backup On, Off Off
VVI Backup Pacing Rate
VVI Backup Amplitude
VVI Backup Pulse Width

30, 35, …, 120 ppm 60 ppm

d

0.5, 1, …, 4, 5, 6 V 4 V

0.03, 0.06, 0.1, 0.2, …,1.6 ms 0.5 ms

b

b

PES Induction Parameters

Chamber Ventricle, Atrium Ventricle
#S1
S1S1
S1S2 Off, 100, 110, …, 600 ms

1, 2, …, 15 8
100, 110, …, 2000 ms 600 ms

400 ms
S2S3 Off, 100, 110, …, 600 ms Off
S3S4 Off, 100, 110, …, 600 ms Off
Pulse Amplitude
Pulse Width

d

0.5, 1, …, 4, 5, 6, 8 V 4 V

0.03, 0.06, 0.1, 0.2, …, 1.6 ms 0.5 ms
Resume at Deliver Enabled, Disabled Enabled
VVI Backup On, Off Off
VVI Backup Pacing Rate
VVI Backup Amplitude
VVI Backup Pulse Width

30, 35, …, 120 ppm 60 ppm

d

0.5, 1, …, 4, 5, 6 V 4 V

0.03, 0.06, 0.1, 0.2, …,1.6 ms 0.5 ms

b

b

35

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 1:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 23. System test and EP study parameters (continued)

Parameter Selectable values Default
Manual therapy parameters

In general, each manual therapy provides the same parameter values as the automatic therapy. See
Table 19.

a

The selectable values for this parameter depend on the programmed pacing mode.

b

The default value for this parameter is set according to the permanently programmed settings for
bradycardia pacing if the device has been interrogated. Otherwise it defaults to the indicated nominal
value.

c

The maximum range value is dependant on the programmed pacing mode.

d

Peak pacing amplitude. When tested per CENELEC standard 45502-2-1, the measured
amplitude A depends upon the programmed amplitude Apand programmed pulse width Wp:
A = Apx [0.9 – (Wpx 0.145 ms-1)].

e

Delivered energy based on a biphasic pulse into a 75
is ±0.25 J.

load. For energy less than 1 J, tolerance



15.5.8 Fixed parameters
Table 24. Fixed parameters

Parameter Fixed value
Fixed blanking periods

Atrial blanking after a sensed atrial event
Atrial blanking after a paced ventricular event
Atrial blanking after high voltage therapy
Ventricular blanking after a sensed ventricular event
Ventricular blanking after a paced atrial event
Ventricular blanking on a high voltage pulse delivery

Fixed bradycardia pacing parameters

Ventricular Safety Pacingintervals
PVC Response (PVARP extension) Extended to 400 ms
PMT Intervention (PVARP extension) Extended to 400 ms

100 ms
30 ms
520 ms
120 ms
30 ms
520 ms

110 ms, 70 ms

a

b
b

Fixed high voltage therapy parameters

Maximum charging period

30 s
Waveform Biphasic
Tilt
Refractory period after V-sense during cardioversion

synchronization
Refractory period after charge end
Refractory period after paced event during charging

or synchronization
Refractory period after charge begins

c

c

Atrial Vulnerable Period
Escape interval after high voltage therapy

50%

200 ms

100 ms

400 ms

400 ms

250 ms

1200 ms

36

198483001 C Medtronic Confidential Composed: 2xxxx-xx-xx1:48

MedtronCRM B,Cxxxx-xx-xx

ECO Market Release DBL:xxxxxxxxxxx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

Table 24. Fixed parameters (continued)

Parameter Fixed value

Suspension of VT detection after defibrillation therapy 17 V. events

Fixed EP Study parameters

T-Shock pacing amplitude
T-Shock pacing pulse width
50 Hz burst pacing interval

Hardware parameters

Atrial rate limit (protective feature)
Ventricular rate limit (protective feature)
Input impedance 100 k

a

The shorter VSP interval takes effect when the pacing rate exceeds the results of the following formula:
60000 / 2 x (Ventricular Pace Blanking + 110) per min.

b

PVARPis only extended to 400 ms if the current PVARP (either the programmed PVARPvalue or the
current Sensor-Varied PVARP value) is less than 400 ms.

c

Does not affect event classification during charging.

d

Peak pacing amplitude. When tested per CENELEC standard 45502-2-1, the measured
amplitude A depends upon the programmed amplitude Apand programmed pulse width Wp:
A = Apx [0.9 – (Wpx 0.145 ms-1)].

e

Does not apply during therapies, programmed high rates, or ventricular safety pacing.

d

8 V

1.6 ms

20 ms

e

171 ppm

e

171 ppm

minimum



37

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

MedtronCRM B,Cxxxx-xx-xx

REGULATORY LABELING REQUIREMENTS

The transmitter covered by this manual has been certified under FCC ID:LF5MICSIMPLANT3 and

IC:3408D-MIMPLANT3.

CE

This transmitter is authorized by rule under the Medical Implant Communications Service (47
C.F.R. Part 95) and must not cause harmful interference to stations operating in the 400.150 -

406.000 MHz band in the Meteorological Aids (i.e. transmitters and receivers used to
communicate weather data), the Meteorological Satellite, or the Earth Exploration Satellite
Services and must accept interference that may be caused by such aids, including interference that
may cause undesired operation. This transmitter shall be used only in accordance with the FCC
Rules governing the Medical Implant Communications Service. Analog and digital voice
communications are prohibited. Although this transmitter has been approved by the Federal
Communications Commission, there is no guarantee that it will not receive interference or that
any particular transmission from this transmitter will be free from interference.

This device may not interfere with stations operating in the 400.150 - 406.000 MHz band in the
Meteorological Aids, Meteorological Satellite, and Earth Exploration Satellite Services and must
accept any interference received, including interference that may cause undesired operation.

ECO Market Release DBL:xxxx-xx-xx
Printing instructions: doc#xxxxxx; refer to ’Implant manuals’ row in the applicable table.

World Headquarters

Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Internet: www.medtronic.com
Tel. [phone]
Fax [phone]

Canada

Medtronic of Canada Ltd.
6733 Kitimat Road
Mississauga, Ontario L5N 1W3
Tel. [phone]
Fax [phone]
Toll-free in Canada: 1-800-268-5346

Europe/Africa/Middle East
Headquarters

Medtronic Europe S.A.
Route du Molliau
CH-1131 Tolochenaz
Switzerland
Internet: www.medtronic.co.uk
Tel. [phone]
Fax [phone]

Medtronic E.C. Authorized

Representative/Distributed by

Medtronic B.V.

Wenckebachstraat 10

6466 NC Kerkrade

The Netherlands

Tel. [phone]

Fax [phone]

Japan

Medtronic Japan

Solid Square West Tower 6F,

580 Horikawa-cho, Saiwai-ku

Kawasaki, Kanagawa 210-0913

Japan

Tel. [phone]

Fax [phone]

Asia

Medtronic International Ltd.

Suite 1602 16/F,ManulifePlaza

The Lee Gardens, 33 Hysan Avenue

Causeway Bay, Hong Kong

Tel. [phone]

Fax [phone]

Australia

Medtronic Australasia Pty. Ltd.

Unit 4/446 Victoria Road

Gladesville NSW 2111

Australia

Tel. [phone]

Fax [phone]

© Medtronic, Inc. 2002

*198483001*

198483001 C Medtronic Confidential Composed:xxxx-xx-xx 11:48

UCX198483001 198483001
2002-02-14

MedtronCRM B,Cxxxx-xx-xx